{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"2.89","value":"1.4"},{"groupId":"OG001","lowerLimit":"0.6","upperLimit":"4.9","value":"2.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"237"}],"units":"Participants"}],"description":"LPF failure was defined as tumor recurrence/progression within the tumor bed. The cumulative incidence (CI) of LPF failure was estimated; 3-year estimates were reported with 95% confidence intervals. Patients with other failure types (e.g., NPF) and with other events prior to LPF failure (e.g., death, second malignancy) were considered as having competing events.","dispersionType":"95% Confidence Interval","groups":[{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the IFRT arms (Treatment Arms I, III, V)","id":"OG000","title":"Involved Field Radiation (IFRT)"},{"description":"Includes eligible patients 3-21 years of age without anaplastic histology or evidence of disseminated or ERD based on central review and randomized to one of the PFRT arms (Treatment Arms II, IV, VI)","id":"OG001","title":"Posterior Fossa Radiation (PFRT)"}],"paramType":"NUMBER","populationDescription":"Eligible and evaluable patients 3-21 yrs of age are included. Patients with anaplastic histology or disseminated/excess residual disease were not evaluable (NE). Arms I/III/V \\[IFRT\\] are combined \\& arms II/IV/VI \\[PFRT\\] are combined. 26 \\& 23 IFRT \\& PFRT pts were NE and were excluded, leaving 227 and 237 eligible and evaluable pts.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Local Posterior Fossa (LPF) Failure Rate","type":"SECONDARY","unitOfMeasure":"percentage 3 yr cumulative incidence"}